Crown Healthcare partners with Impact Fund Denmark to Advance Local Pharmaceutical / Medical devices Production
Crown Healthcare has taken a major step toward strengthening Kenya’s pharmaceutical capacity with the construction of a new medicine manufacturing facility in Nairobi. Supported by a USD 10 million (approximately 65 million DKK) investment from Impact Fund Denmark, the project is already well underway, signaling a significant shift in local medicine production.
Kenya currently imports nearly 80% of its medicines and medical devices, a dependency that increases vulnerability to price volatility, counterfeit products, and global supply chain disruptions. Local production is therefore critical to ensuring affordable, high-quality, and reliable access to life-saving medicines.
The new plant will manufacture a range of essential pharmaceuticals for both Kenya and the broader East African region, directly contributing to improved health security. The facility is also expected to generate over 600 local jobs across manufacturing, quality assurance, logistics, and technical operations – representing a major economic boost.
This investment aligns with growing continental efforts to enhance Africa’s pharmaceutical self-sufficiency and reduce dependence on external supply chains. By bringing essential production closer to home, Kenya will be better positioned to safeguard the availability of critical medicines for its expanding population.
Crown Healthcare’s expansion marks a meaningful step toward building a more resilient, sustainable, and self-reliant health ecosystem for East Africa, strengthening both the medical devices and pharmaceuticals landscape.
This milestone has been made possible through the exceptional leadership and dedicated work of Lisbeth Erlands, Sam Githinji, Ida Møller Hammerberg, Shilen Thakerar, and Francis Muthiani.